Literature DB >> 22717200

The role of diet and nutrient composition in nonalcoholic Fatty liver disease.

Erin Marie McCarthy1, Mary E Rinella.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the developed world. NAFLD is tightly linked to insulin resistance and considered to be the hepatic manifestation of the metabolic syndrome. The cornerstone of any treatment regimen for patients with NAFLD is lifestyle modification focused on weight loss, exercise, and improving insulin sensitivity. Here we review the literature and discuss the role of diet and nutrient composition in the management of NAFLD. Because there are currently no specific dietary guidelines for NAFLD, this review proposes a dietary framework for patients with NAFLD based on the available evidence and extrapolates from dietary guidelines aimed at reducing insulin resistance and cardiovascular risk.
Copyright © 2012 Academy of Nutrition and Dietetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22717200     DOI: 10.1016/j.jada.2011.10.007

Source DB:  PubMed          Journal:  J Acad Nutr Diet        ISSN: 2212-2672            Impact factor:   4.910


  51 in total

1.  Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012.

Authors:  Kenichi Nishioji; Yoshio Sumida; Mai Kamaguchi; Naomi Mochizuki; Masao Kobayashi; Takeshi Nishimura; Kanji Yamaguchi; Yoshito Itoh
Journal:  J Gastroenterol       Date:  2014-03-12       Impact factor: 7.527

Review 2.  Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults.

Authors:  Elena S George; Adrienne Forsyth; Catherine Itsiopoulos; Amanda J Nicoll; Marno Ryan; Siddharth Sood; Stuart K Roberts; Audrey C Tierney
Journal:  Adv Nutr       Date:  2018-01-01       Impact factor: 8.701

Review 3.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

Review 4.  Clinical approaches to non-alcoholic fatty liver disease.

Authors:  Katherine J P Schwenger; Johane P Allard
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 5.  Mediterranean diet and non-alcoholic fatty liver disease: new therapeutic option around the corner?

Authors:  Francesco Sofi; Alessandro Casini
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

6.  Influence of dietary saturated fat content on adiposity, macrophage behavior, inflammation, and metabolism: composition matters.

Authors:  Reilly T Enos; J Mark Davis; Kandy T Velázquez; Jamie L McClellan; Stani D Day; Kevin A Carnevale; E Angela Murphy
Journal:  J Lipid Res       Date:  2012-10-28       Impact factor: 5.922

7.  Pathophysiology of NASH: perspectives for a targeted treatment.

Authors:  Fabio Marra; Sophie Lotersztajn
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

8.  Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration.

Authors:  Y Wang; E T Parlevliet; J J Geerling; S J L van der Tuin; H Zhang; V Bieghs; A H M Jawad; R Shiri-Sverdlov; I Bot; S C A de Jager; L M Havekes; J A Romijn; K Willems van Dijk; P C N Rensen
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 9.  A Fad too Far? Dietary Strategies for the Prevention and Treatment of NAFLD.

Authors:  Mary P Moore; Rory P Cunningham; Ryan J Dashek; Justine M Mucinski; R Scott Rector
Journal:  Obesity (Silver Spring)       Date:  2020-09-06       Impact factor: 5.002

Review 10.  From NASH to HCC: current concepts and future challenges.

Authors:  Quentin M Anstee; Helen L Reeves; Elena Kotsiliti; Olivier Govaere; Mathias Heikenwalder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.